Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q1 2021 · 10-Q
Revenue$38.43M$38.43M+57.5% vs Q1 2020 Net Income-$71.76M-$71.76MN/M vs Q1 2020 EPS Diluted-$0.78-$0.78N/M vs Q1 2020 Operating Income-$70,427,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Free Cash Flowderived-$45,502,000N/M Margins · derivedOperating margin-183.3%+149.0 pt vs Q1 2020
Net margin-186.7%+134.4 pt vs Q1 2020
ended Mar 31, 2021 · filed May 10, 2021 · 40 d after period end